Maya Makov-Assif
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Maya Makov-Assif has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Noa Dagan
Stein Faculty of Computer and Information Science, Ben-Gurion University of the Negev, Beer-Sheva, Israel
2 shared publications - Ran D. Balicer
Clalit Research Institute, Innovation Division, Clalit Health Services, Ramat Gan, Israel
2 shared publications - Ben Y. Reis
Computational Health Informatics Program, Boston Children's Hospital; Department of Pediatrics, Harvard Medical School
1 shared publication - Doron Netzer
Community Medicine Division, Clalit Health Services, Tel Aviv, Israel
1 shared publication - Marc Lipsitch
Harvard University
1 shared publication - Michael Leshchinsky
Clalit Research Institute, Innovation Division, Clalit Health Services, Tel Aviv, Israel
1 shared publication
Latest Publications
- 25 January 2024
- Published by Massachusetts Medical Society in NEJM AI
- Vol. 1 (2)
Prospective Evaluation of Machine Learning for Public Health Screening: Identifying Unknown Hepatitis C Carriers
- 25 January 2024
- Published by Massachusetts Medical Society in NEJM AI
- Vol. 1 (2)
Prospective Evaluation of Machine Learning for Public Health Screening: Identifying Unknown Hepatitis C Carriers
- 7 November 2021
- Published by Taylor & Francis in Infectious Diseases
- Vol. 54 (3) , 205-212
The association between real-time reverse transcriptase polymerase chain reaction cycle threshold values, symptoms and disease severity among COVID-19 patients in the community: a retrospective cohort study
COVID-19 continues to spread throughout the world. Real-time reverse transcriptase polymerase chain reaction (RT-PCR) is used to diagnose COVID-19, with its cycle threshold (Ct) value inversely related to the viral load. The association between Ct values and COVID-19 related outcomes has been studied in the hospital setting but less so in the community. We aimed to estimate the association between Ct values and the severity of community-diagnosed COVID-19 to provide evidence on the utility of Ct testing in this setting. This was a retrospective cohort study based on data from Israel’s largest health organization. The study population included 34,658 individuals who tested positive for COVID-19 by RT-PCR and had available Ct values between June 1st and December 21st, 2020. Outcomes included COVID-19 related symptoms, hospitalization, severe disease, and death. Ct values were modelled both as discrete and continuous exposures. After adjusting for known risk factors for severe COVID-19, low Ct values were associated with symptomatic disease (odds ratio [OR]: 1.51; 95% confidence interval [CI]:1.21–1.84), hospitalization (OR: 1.27; 95%CI: 1.12–1.49), severe disease (OR: 1.80; 95%CI: 1.43–2.27), and death (OR: 1.64; 95%CI: 1.06–2.59). By modelling the exposure as continuous, we noticed a dose-response relationship, with the risk gradually rising with lower Ct values. This study found a significant association between low Ct values and severe COVID-19 related outcomes, with a dose-response relationship. This suggests that Ct values could be helpful in identifying high-risk patients diagnosed in the community.
- 7 November 2021
- Published by Taylor & Francis in Infectious Diseases
- Vol. 54 (3) , 205-212
The association between real-time reverse transcriptase polymerase chain reaction cycle threshold values, symptoms and disease severity among COVID-19 patients in the community: a retrospective cohort study
COVID-19 continues to spread throughout the world. Real-time reverse transcriptase polymerase chain reaction (RT-PCR) is used to diagnose COVID-19, with its cycle threshold (Ct) value inversely related to the viral load. The association between Ct values and COVID-19 related outcomes has been studied in the hospital setting but less so in the community. We aimed to estimate the association between Ct values and the severity of community-diagnosed COVID-19 to provide evidence on the utility of Ct testing in this setting. This was a retrospective cohort study based on data from Israel’s largest health organization. The study population included 34,658 individuals who tested positive for COVID-19 by RT-PCR and had available Ct values between June 1st and December 21st, 2020. Outcomes included COVID-19 related symptoms, hospitalization, severe disease, and death. Ct values were modelled both as discrete and continuous exposures. After adjusting for known risk factors for severe COVID-19, low Ct values were associated with symptomatic disease (odds ratio [OR]: 1.51; 95% confidence interval [CI]:1.21–1.84), hospitalization (OR: 1.27; 95%CI: 1.12–1.49), severe disease (OR: 1.80; 95%CI: 1.43–2.27), and death (OR: 1.64; 95%CI: 1.06–2.59). By modelling the exposure as continuous, we noticed a dose-response relationship, with the risk gradually rising with lower Ct values. This study found a significant association between low Ct values and severe COVID-19 related outcomes, with a dose-response relationship. This suggests that Ct values could be helpful in identifying high-risk patients diagnosed in the community.